Document
false0000832101Common Stock, par value $.01 per shareNew York Stock ExchangeIEX 0000832101 2019-10-29 2019-10-29


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report: October 29, 2019
(Date of earliest event reported)
 
 
IDEX CORPORATION
(Exact name of registrant as specified in its charter)
 
 
Delaware
 
1-10235
 
36-3555336
(State or other jurisdiction
 
(Commission File Number)
 
(IRS Employer
of incorporation)
 
 
 
Identification No.)
1925 W. Field Court, Suite 200
Lake Forest, Illinois 60045
(Address of principal executive offices, including zip code)
(847498-7070
(Registrant’s telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
 
Trading Symbol(s)
 
Name of Each Exchange on Which Registered
Common Stock, par value $.01 per share
 
IEX
 
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
 
 
 
 
 
 
Emerging growth company
 
 
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

 





Item 2.02 – Results of Operations and Financial Condition.

On October 29, 2019, IDEX Corporation (the “Company”) issued a press release announcing financial results for the period ended September 30, 2019.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report furnished pursuant to Item 2.02 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.


Item 7.01 – Regulation FD Disclosure.

Q3 2019 Presentation Slides

Presentation slides discussing IDEX Corporation’s quarterly operating results are attached to this Current Report on Form 8-K as Exhibit 99.2 and are incorporated herein by reference.

The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand the future prospects of a company and make informed investment decisions. This Current Report and the Exhibits hereto may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the company believes,” “the company intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors, and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company's results, particularly in light of the low levels of order backlogs it typically maintains; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in IDEX’s most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included in this Current Report and the Exhibits hereto are only made as of the date of this Current Report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented herein.

The information in this Current Report furnished pursuant to Items 7.01 and 9.01 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.





Item 9.01 – Financial Statements and Exhibits.

(a)
Exhibits

99.1
Press release dated October 29, 2019 announcing IDEX Corporation’s quarterly operating results

99.2
Presentation slides of IDEX Corporation’s quarterly operating results






SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IDEX CORPORATION
 
 
 
 
By:
/s/  WILLIAM K. GROGAN
 
 
William K. Grogan
 
 
Senior Vice President and Chief Financial Officer
October 30, 2019
 
 






EXHBIT INDEX

Exhibit
Number
 
Description
 
 
 
 
 



Exhibit


https://cdn.kscope.io/21459dbd199dbc6d1547ffa08a9eb1b9-idexlogowtaglinejul28.jpg                                

For further information:         TRADED: NYSE (IEX)                            EX-99.1    
Investor Contact:                
William K. Grogan                         
Senior Vice President and Chief Financial Officer                     
(847) 498-7070        

TUESDAY, OCTOBER 29, 2019

IDEX REPORTS THIRD QUARTER RESULTS;
DELIVERS RECORD ADJUSTED GROSS AND OPERATING MARGIN;
REPORTED EPS OF $1.37 WITH ADJUSTED EPS OF $1.52


LAKE FOREST, IL, OCTOBER 29 - IDEX Corporation (NYSE: IEX) today announced its financial results for the three month period ended September 30, 2019.

Third Quarter 2019 Highlights
Sales were flat overall and organically
Gross margin was 45.2 percent with adjusted gross margin of 45.7 percent, an all-time high
Reported operating margin was 22.7 percent with adjusted operating margin of 25.2 percent, up 120 bps
Reported EPS was $1.37 with adjusted EPS of $1.52, up 8 percent
Cash from operations of $157.1 million led to FCF of $146.0 million, an all-time high

Third Quarter 2019
Orders of $586.1 million were down 5 percent compared with the prior year period (-5 percent organic, +1 percent acquisitions and -1 percent foreign currency translation).

Sales of $624.2 million were flat compared with the prior year period (flat organic, +1 percent acquisitions and -1 percent foreign currency translation).
  
Gross margin of 45.2 percent was up 20 basis points compared with the prior year period. Excluding a $3.3 million pre-tax fair value inventory step-up charge related to the Velcora acquisition, adjusted gross margin of 45.7 percent was up 70 basis points primarily due to price and productivity initiatives, partially offset by higher engineering investments.

Operating income of $141.8 million resulted in an operating margin of 22.7 percent. Excluding the $3.3 million fair value inventory step-up charge and $12.0 million of restructuring expenses, adjusted operating income was $157.1 million with an adjusted operating margin of 25.2 percent, up 120 basis points compared with the adjusted prior year period primarily due to gross margin expansion and lower variable compensation costs as well as an overall tighter cost control environment. Adjusted operating income drove adjusted EBITDA of $175.4 million which was 28 percent of sales and covered interest expense by over 15 times.

Provision for income taxes of $24.0 million in the third quarter of 2019 resulted in an effective tax rate (ETR) of 18.6 percent, which was lower than the prior year period ETR of 20.2 percent primarily due to a change in U.S. Treasury regulations as well as the mix of global pre-tax income among jurisdictions. The third quarter 2019 ETR of 18.6 percent was lower than our previously guided ETR of 22.5 percent, which provided 6 cents of EPS favorability. This was primarily due to higher excess tax benefits from greater than expected stock option exercises in the third quarter of 2019 as well as a favorable impact from the 2018 income tax return-to-provision adjustment.






Net income was $105.2 million which resulted in EPS of $1.37. Excluding the fair value inventory step-up charge and restructuring expenses, adjusted EPS was $1.52, an increase of 11 cents, or 8 percent, from the adjusted prior year period EPS.

Cash from operations of $157.1 million led to free cash flow of $146.0 million, which was up 28 percent from the prior year period and 125 percent of adjusted net income. The increase in free cash flow was primarily due to favorable operating working capital and lower capital expenditures in the third quarter of 2019.

“The third quarter was all about operational execution which allowed us to expand both gross and operating margins to all-time highs. Adjusted gross margin of 45.7 percent and adjusted operating margin of 25.2 percent were up 70 and 120 basis points, respectively. This margin expansion helped us deliver record adjusted EPS of $1.52. Free cash flow was strong with a conversion rate of 125 percent of adjusted net income, up 28 percent from the prior year period. On the commercial side, demand was challenging in the third quarter due to the continued softening of the global economy. The unresolved trade conflicts continued to weigh on global growth in most of our end markets, as companies are delaying investments due to the unclear outlook. As a result, organic sales in the third quarter were flat compared to the prior year period. However, I am very pleased with how the team performed in this challenging environment and confident that we will keep delivering strong operating results during these volatile times.  
 
 
M&A continues to be a key priority of the Company. In July, we acquired Velcora and are currently in the process of integrating its operations into our existing Sealing Solutions platform within the Health & Science Technologies segment. We have approximately $2 billion of capacity to support additional opportunities based on existing cash, availability under our revolver and a low debt leverage ratio.
 
 
Based on recent order trends and instability within the macro-economic environment, we now project approximately 2 percent organic revenue growth for 2019, with flat organic sales in the fourth quarter. We have narrowed full year 2019 adjusted EPS to $5.80 to $5.82, with fourth quarter EPS of $1.33 to $1.35.”
 
 
 
Andrew K. Silvernail
 
Chairman and Chief Executive Officer

Third Quarter 2019 Segment Highlights

Fluid & Metering Technologies
Sales of $240.9 million reflected a 1 percent increase compared to the third quarter of 2018 (+2 percent organic and -1 percent foreign currency translation).
Operating income of $77.5 million resulted in an operating margin of 32.2 percent, a 270 basis point increase compared to the adjusted prior year period primarily due to price and productivity initiatives, partially offset by higher engineering investments.
EBITDA of $82.7 million resulted in an EBITDA margin of 34.3 percent, a 270 basis point increase compared to the adjusted prior year period primarily due to increased operating income.

Health & Science Technologies
Sales of $229.6 million reflected a 3 percent increase compared to the third quarter of 2018 (+1 percent organic, +3 percent acquisition and -1 percent foreign currency translation).
Operating income of $40.2 million resulted in an operating margin of 17.5 percent. Excluding the $3.3 million fair value inventory step-up charge and $11.2 million of restructuring expenses, adjusted operating income was $54.7 million with an adjusted operating margin of 23.8 percent, a 30 basis point increase compared to the adjusted prior year period primarily due to higher volume and price, partially offset by higher engineering investments and increased amortization due to the acquisition.
EBITDA of $49.2 million resulted in an EBITDA margin of 21.4 percent. Excluding the $3.3 million fair value inventory step-up charge and $11.2 million of restructuring expenses, adjusted EBITDA of $63.7 million resulted in an adjusted EBITDA margin of 27.8 percent, a 40 basis point increase compared to the adjusted prior year period primarily due to increased operating income.






Fire & Safety/Diversified Products
Sales of $154.5 million reflected a 5 percent decrease compared to the third quarter of 2018 (-3 percent organic and -2 percent foreign currency translation) mainly attributable to large project orders within our dispensing and fire businesses in the prior year period not repeating.
Operating income of $42.0 million resulted in an operating margin of 27.2 percent. Excluding $0.1 million of restructuring expenses, adjusted operating income was $42.1 million with an adjusted operating margin of 27.2 percent, a 50 basis point decrease compared to the adjusted prior year period primarily due to reduced volume.
EBITDA of $45.6 million resulted in an EBITDA margin of 29.5 percent. Excluding $0.1 million of restructuring expenses, adjusted EBITDA of $45.7 million resulted in an adjusted EBITDA margin of 29.6 percent, a 10 basis point decrease compared to the adjusted prior year period primarily due to a decrease in operating income.

For the third quarter of 2019, Fluid & Metering Technologies contributed 38 percent of sales, 49 percent of operating income and 47 percent of EBITDA; Health & Science Technologies accounted for 37 percent of sales, 25 percent of operating income and 28 percent of EBITDA; and Fire & Safety/Diversified Products represented 25 percent of sales, 26 percent of operating income and 25 percent of EBITDA.

Acquisition
In July 2019, the Company acquired Velcora Holding AB and its operating subsidiaries, Roplan and Steridose. Roplan is a global manufacturer of custom mechanical and shaft seals for a variety of end markets including food & beverage, marine, chemical, wastewater and water treatment. Steridose develops engineered hygienic mixers and valves for the global biopharmaceutical industry. With annual revenue of approximately $40 million, both businesses operate within the Health & Science Technologies segment. In connection with this acquisition, the Company had to write up inventory to its fair value which resulted in a $3.3 million fair value inventory step-up charge in the quarter.

Restructuring Actions
The Company recorded $12.0 million and $14.1 million of restructuring expenses in the third quarter and nine months ended September 30, 2019, respectively, as part of initiatives that supported the implementation of key strategic efforts designed to facilitate long-term, sustainable growth through cost reduction actions, primarily consisting of employee reductions, facility rationalization and impairment charges. These restructuring actions included a $9.7 million impairment charge in the third quarter related to the winding down of a business within the Health & Science Technologies segment.

Non-U.S. GAAP Measures of Financial Performance
The Company supplements certain U.S. GAAP financial performance metrics with non-U.S. GAAP financial performance metrics in order to provide investors with better insight and increased transparency while also allowing for a more comprehensive understanding of the financial information used by management in its decision making. Reconciliations of non-U.S. GAAP financial performance metrics to their most comparable U.S. GAAP financial performance metrics are defined and presented below and should not be considered a substitute for, nor superior to, the financial data prepared in accordance with U.S. GAAP. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.

Organic orders and sales are calculated excluding amounts from acquired or divested businesses during the first twelve months of ownership or divestiture and the impact of foreign currency translation.
Adjusted gross margin is calculated as gross margin plus the fair value inventory step-up charge.
Adjusted operating income is calculated as operating income plus the fair value inventory step-up charge plus restructuring expenses.
Adjusted operating margin is calculated as adjusted operating income divided by net sales.
Adjusted net income is calculated as net income plus the fair value inventory step-up charge plus restructuring expenses, net of the statutory tax expense or benefit.





EBITDA is calculated as net income plus interest expense plus provision for income taxes plus depreciation and amortization. We reconciled EBITDA to net income on a consolidated basis as we do not allocate consolidated interest expense or consolidated provision for income taxes to our segments.
Adjusted EBITDA is calculated as EBITDA plus the fair value inventory step-up charge plus restructuring expenses.
Free cash flow is calculated as cash flow from operating activities less capital expenditures.


Table 1: Reconciliations of the Change in Net Sales to Organic Net Sales
 
Three Months Ended September 30, 2019
 
Nine Months Ended September 30, 2019
 
FMT
 
HST
 
FSDP
 
IDEX
 
FMT
 
HST
 
FSDP
 
IDEX
Change in net sales
1
 %
 
3
 %
 
(5
)%
 
 %
 
2
 %
 
2
 %
 
(2
)%
 
1
 %
 - Net impact from acquisitions
 %
 
3
 %
 
 %
 
1
 %
 
 %
 
2
 %
 
 %
 
1
 %
 - Impact from FX
(1
)%
 
(1
)%
 
(2
)%
 
(1
)%
 
(2
)%
 
(2
)%
 
(2
)%
 
(2
)%
Change in organic net sales
2
 %
 
1
 %
 
(3
)%
 
 %
 
4
 %
 
2
 %
 
 %
 
2
 %



Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Margin (dollars in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Gross profit
$
281,978

 
$
280,233

 
$
858,149

 
$
844,252

+ Fair value inventory step-up charge
3,340

 

 
3,340

 

Adjusted gross profit
$
285,318

 
$
280,233

 
$
861,489

 
$
844,252

 
 
 
 
 
 
 
 
Net sales
$
624,246

 
$
622,888

 
$
1,888,576

 
$
1,869,572

 
 
 
 
 
 
 
 
Gross profit margin
45.2
%
 
45.0
%
 
45.4
%
 
45.2
%
Adjusted gross profit margin
45.7
%
 
45.0
%
 
45.6
%
 
45.2
%






Table 3: Reconciliations of Reported-to-Adjusted Operating Income and Margin (dollars in thousands)
 
Three Months Ended September 30,
 
2019
 
2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Reported operating income (loss)
$
77,481

 
$
40,170

 
$
41,967

 
$
(17,853
)
 
$
141,765

 
$
69,755

 
$
49,144

 
$
44,726

 
$
(18,492
)
 
$
145,133

 + Restructuring expenses

 
11,196

 
104

 
656

 
11,956

 
827

 
3,116

 
60

 
618

 
4,621

 + Fair value inventory step-up charge

 
3,340

 

 

 
3,340

 

 

 

 

 

Adjusted operating income (loss)
$
77,481

 
$
54,706

 
$
42,071

 
$
(17,197
)
 
$
157,061

 
$
70,582

 
$
52,260

 
$
44,786

 
$
(17,874
)
 
$
149,754

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
240,861

 
$
229,610

 
$
154,543

 
$
(768
)
 
$
624,246

 
$
239,213

 
$
222,426

 
$
161,832

 
$
(583
)
 
$
622,888

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reported operating margin
32.2
%
 
17.5
%
 
27.2
%
 
n/m

 
22.7
%
 
29.2
%
 
22.1
%
 
27.6
%
 
n/m

 
23.3
%
Adjusted operating margin
32.2
%
 
23.8
%
 
27.2
%
 
n/m

 
25.2
%
 
29.5
%
 
23.5
%
 
27.7
%
 
n/m

 
24.0
%
 
Nine Months Ended September 30,
 
2019
 
2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Reported operating income (loss)
$
223,493

 
$
151,087

 
$
125,909

 
$
(55,659
)
 
$
444,830

 
$
207,149

 
$
153,519

 
$
130,162

 
$
(61,183
)
 
$
429,647

 + Restructuring expenses
930

 
11,526

 
923

 
703

 
14,082

 
1,313

 
5,298

 
427

 
1,213

 
8,251

 + Fair value inventory step-up charge

 
3,340

 

 

 
3,340

 

 

 

 

 

Adjusted operating income (loss)
$
224,423

 
$
165,953

 
$
126,832

 
$
(54,956
)
 
$
462,252

 
$
208,462

 
$
158,817

 
$
130,589

 
$
(59,970
)
 
$
437,898

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
729,572

 
$
687,153

 
$
474,745

 
$
(2,894
)
 
$
1,888,576

 
$
714,346

 
$
670,904

 
$
485,305

 
$
(983
)
 
$
1,869,572

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reported operating margin
30.6
%
 
22.0
%
 
26.5
%
 
n/m

 
23.6
%
 
29.0
%
 
22.9
%
 
26.8
%
 
n/m

 
23.0
%
Adjusted operating margin
30.8
%
 
24.2
%
 
26.7
%
 
n/m

 
24.5
%
 
29.2
%
 
23.7
%
 
26.9
%
 
n/m

 
23.4
%

Table 4: Reconciliations of Reported-to-Adjusted Net Income and EPS (in thousands, except EPS)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Reported net income
$
105,194

 
$
106,352

 
$
328,671

 
$
312,436

 + Restructuring expenses
11,956

 
4,621

 
14,082

 
8,251

 + Tax impact on restructuring expenses
(2,776
)
 
(1,130
)
 
(3,336
)
 
(2,003
)
 + Fair value inventory step-up charge
3,340

 

 
3,340

 

 + Tax impact on fair value inventory step-up charge
(735
)
 

 
(735
)
 

Adjusted net income
$
116,979

 
$
109,843

 
$
342,022

 
$
318,684






 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Reported diluted EPS
$
1.37

 
$
1.37

 
$
4.30

 
$
4.02

 + Restructuring expenses
0.16

 
0.06

 
0.18

 
0.11

 + Tax impact on restructuring expenses
(0.04
)
 
(0.02
)
 
(0.04
)
 
(0.03
)
 + Fair value inventory step-up charge
0.04

 

 
0.04

 

 + Tax impact on fair value inventory step-up charge
(0.01
)
 

 
(0.01
)
 

Adjusted diluted EPS
$
1.52

 
$
1.41

 
$
4.47

 
$
4.10

 
 
 
 
 
 
 
 
Diluted weighted average shares outstanding
76,577

 
77,709

 
76,415

 
77,717


Table 5: Reconciliations of EBITDA to Net Income (dollars in thousands)
 
Three Months Ended September 30,
 
2019
 
2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Reported operating income (loss)
$
77,481

 
$
40,170

 
$
41,967

 
$
(17,853
)
 
$
141,765

 
$
69,755

 
$
49,144

 
$
44,726

 
$
(18,492
)
 
$
145,133

 - Other (income) expense - net
295

 
1,272

 
(92
)
 
(256
)
 
1,219

 
411

 
780

 
342

 
(599
)
 
934

 + Depreciation and amortization
5,507

 
10,296

 
3,566

 
154

 
19,523

 
5,500

 
9,381

 
3,541

 
184

 
18,606

EBITDA
82,693

 
49,194

 
45,625

 
(17,443
)
 
160,069

 
74,844

 
57,745

 
47,925

 
(17,709
)
 
162,805

 - Interest expense
 
 
 
 
 
 
 
 
11,330

 
 
 
 
 
 
 
 
 
10,958

 - Provision for income taxes
 
 
 
 
 
 
 
 
24,022

 
 
 
 
 
 
 
 
 
26,889

 - Depreciation and amortization
 
 
 
 
 
 
 
 
19,523

 
 
 
 
 
 
 
 
 
18,606

Reported net income
 
 
 
 
 
 
 
 
$
105,194

 
 
 
 
 
 
 
 
 
$
106,352

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
240,861

 
$
229,610

 
$
154,543

 
$
(768
)
 
$
624,246

 
$
239,213

 
$
222,426

 
$
161,832

 
$
(583
)
 
$
622,888

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reported operating margin
32.2
%
 
17.5
%
 
27.2
%
 
n/m

 
22.7
%
 
29.2
%
 
22.1
%
 
27.6
%
 
n/m

 
23.3
%
EBITDA margin
34.3
%
 
21.4
%
 
29.5
%
 
n/m

 
25.6
%
 
31.3
%
 
26.0
%
 
29.6
%
 
n/m

 
26.1
%
 
Nine Months Ended September 30,
 
2019
 
2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Reported operating income (loss)
$
223,493

 
$
151,087

 
$
125,909

 
$
(55,659
)
 
$
444,830

 
$
207,149

 
$
153,519

 
$
130,162

 
$
(61,183
)
 
$
429,647

 - Other (income) expense - net
612

 
1,636

 
273

 
(1,820
)
 
701

 
1,056

 
(280
)
 
(3,324
)
 
(1,017
)
 
(3,565
)
 + Depreciation and amortization
16,653

 
29,438

 
10,745

 
510

 
57,346

 
16,901

 
30,860

 
10,912

 
557

 
59,230

EBITDA
239,534

 
178,889

 
136,381

 
(53,329
)
 
501,475

 
222,994

 
184,659

 
144,398

 
(59,609
)
 
492,442

 - Interest expense
 
 
 
 
 
 
 
 
33,262

 
 
 
 
 
 
 
 
 
33,098

 - Provision for income taxes
 
 
 
 
 
 
 
 
82,196

 
 
 
 
 
 
 
 
 
87,678

 - Depreciation and amortization
 
 
 
 
 
 
 
 
57,346

 
 
 
 
 
 
 
 
 
59,230

Reported net income
 
 
 
 
 
 
 
 
$
328,671

 
 
 
 
 
 
 
 
 
$
312,436

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
729,572

 
$
687,153

 
$
474,745

 
$
(2,894
)
 
$
1,888,576

 
$
714,346

 
$
670,904

 
$
485,305

 
$
(983
)
 
$
1,869,572

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reported operating margin
30.6
%
 
22.0
%
 
26.5
%
 
n/m

 
23.6
%
 
29.0
%
 
22.9
%
 
26.8
%
 
n/m

 
23.0
%
EBITDA margin
32.8
%
 
26.0
%
 
28.7
%
 
n/m

 
26.6
%
 
31.2
%
 
27.5
%
 
29.8
%
 
n/m

 
26.3
%






Table 6: Reconciliations of EBITDA to Adjusted EBITDA (dollars in thousands)
 
Three Months Ended September 30,
 
2019
 
2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
EBITDA
$
82,693

 
$
49,194

 
$
45,625

 
$
(17,443
)
 
$
160,069

 
$
74,844

 
$
57,745

 
$
47,925

 
$
(17,709
)
 
$
162,805

 + Restructuring expenses

 
11,196

 
104

 
656

 
11,956

 
827

 
3,116

 
60

 
618

 
4,621

 + Fair value inventory step-up charge

 
3,340

 

 

 
3,340

 

 

 

 

 

Adjusted EBITDA
$
82,693

 
$
63,730

 
$
45,729

 
$
(16,787
)
 
$
175,365

 
$
75,671

 
$
60,861

 
$
47,985

 
$
(17,091
)
 
$
167,426

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted EBITDA margin
34.3
%
 
27.8
%
 
29.6
%
 
n/m

 
28.1
%
 
31.6
%
 
27.4
%
 
29.7
%
 
n/m

 
26.9
%
 
Nine Months Ended September 30,
 
2019
 
2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
EBITDA
$
239,534

 
$
178,889

 
$
136,381

 
$
(53,329
)
 
$
501,475

 
$
222,994

 
$
184,659

 
$
144,398

 
$
(59,609
)
 
$
492,442

 + Restructuring expenses
930

 
11,526

 
923

 
703

 
14,082

 
1,313

 
5,298

 
427

 
1,213

 
8,251

 + Fair value inventory step-up charge

 
3,340

 

 

 
3,340

 

 

 

 

 

Adjusted EBITDA
$
240,464

 
$
193,755

 
$
137,304

 
$
(52,626
)
 
$
518,897

 
$
224,307

 
$
189,957

 
$
144,825

 
$
(58,396
)
 
$
500,693

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted EBITDA margin
33.0
%
 
28.2
%
 
28.9
%
 
n/m

 
27.5
%
 
31.4
%
 
28.3
%
 
29.8
%
 
n/m

 
26.8
%

Table 7: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (in thousands)
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
June 30,
 
September 30,
 
2019
 
2018
 
2019
 
2019
 
2018
Cash flows from operating activities
$
157,064

 
$
133,327

 
$
131,175

 
$
376,902

 
$
325,753

 - Capital expenditures
11,031

 
18,888

 
12,867

 
36,773

 
39,856

Free cash flow
$
146,033

 
$
114,439

 
$
118,308

 
$
340,129

 
$
285,897



Conference Call to be Broadcast over the Internet
IDEX will broadcast its third quarter earnings conference call over the Internet on Wednesday, October 30, 2019 at 9:30 a.m. CT. Chairman and Chief Executive Officer Andy Silvernail and Senior Vice President and Chief Financial Officer William Grogan will discuss the Company’s recent financial performance and respond to questions from the financial analyst community. IDEX invites interested investors to listen to the call and view the accompanying slide presentation, which will be carried live on its website at www.idexcorp.com. Those who wish to participate should log on several minutes before the discussion begins. After clicking on the presentation icon, investors should follow the instructions to ensure their systems are set up to hear the event and view the presentation slides, or download the correct applications at no charge. Investors will also be able to hear a replay of the call by dialing 877.660.6853 (or 201.612.7415 for international participants) using the ID #13684164.






Forward-Looking Statements
This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company's results, particularly in light of the low levels of order backlogs it typically maintains; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K filed with the SEC and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

About IDEX
IDEX (NYSE: IEX) is a company that has undoubtedly touched your life in some way. In fact, IDEX businesses make thousands of products that are mission-critical components in everyday activities. Chances are the car you’re driving has a BAND-IT® clamp holding your side airbag safely in place. If you were ever in a car accident, a Hurst Jaws of Life® rescue tool may have saved your life. If you or a family member is battling cancer, your doctor may have tested your DNA in a quest to find the best targeted medicine for you. It’s likely your DNA test was run on equipment that contains components made by our growing IDEX Health & Science team. Founded in 1988 with three small, entrepreneurial manufacturing companies, we’re proud to say that we now call 40 diverse businesses around the world part of the IDEX family. With 7,000 employees and manufacturing operations in more than 20 countries, IDEX is a high-performing, global $2+ billion company committed to making trusted solutions that improve lives. IDEX shares are traded on the New York Stock Exchange under the symbol “IEX”.

For further information on IDEX Corporation and its business units, visit the company’s website at www.idexcorp.com.



(Financial reports follow)





IDEX CORPORATION
Condensed Consolidated Statements of Operations
(in thousands except per share amounts)
(unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Net sales
$
624,246

 
$
622,888

 
$
1,888,576

 
$
1,869,572

Cost of sales
342,268

 
342,655

 
1,030,427

 
1,025,320

Gross profit
281,978

 
280,233

 
858,149

 
844,252

Selling, general and administrative expenses
128,257

 
130,479

 
399,237

 
406,354

Restructuring expenses
11,956

 
4,621

 
14,082

 
8,251

Operating income
141,765

 
145,133

 
444,830

 
429,647

Other (income) expense - net
1,219

 
934

 
701

 
(3,565
)
Interest expense
11,330

 
10,958

 
33,262

 
33,098

Income before income taxes
129,216

 
133,241

 
410,867

 
400,114

Provision for income taxes
24,022

 
26,889

 
82,196

 
87,678

Net income
$
105,194

 
$
106,352

 
$
328,671

 
$
312,436

 
 
 
 
 
 
 
 
Earnings per Common Share:
 
 
 
 
 
 
 
Basic earnings per common share
$
1.39

 
$
1.39

 
$
4.34

 
$
4.07

Diluted earnings per common share
$
1.37

 
$
1.37

 
$
4.30

 
$
4.02

 
 
 
 
 
 
 
 
Share Data:
 
 
 
 
 
 
 
Basic weighted average common shares outstanding
75,698

 
76,562

 
75,532

 
76,507

Diluted weighted average common shares outstanding
76,577

 
77,709

 
76,415

 
77,717







IDEX CORPORATION
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

 
September 30, 2019
 
December 31, 2018
Assets
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
515,985

 
$
466,407

Receivables - net
317,305

 
312,192

Inventories
303,494

 
279,995

Other current assets
53,840

 
33,938

Total current assets
1,190,624

 
1,092,532

Property, plant and equipment - net
273,330

 
281,220

Goodwill and intangible assets
2,165,298

 
2,081,282

Other noncurrent assets
84,643

 
18,823

Total assets
$
3,713,895

 
$
3,473,857

 
 
 
 
Liabilities and shareholders' equity
 
 
 
Current liabilities
 
 
 
Trade accounts payable
$
147,079

 
$
143,196

Accrued expenses
185,156

 
187,536

Short-term borrowings
417

 
483

Dividends payable
38,018

 
33,446

Total current liabilities
370,670

 
364,661

Long-term borrowings
848,728

 
848,335

Other noncurrent liabilities
331,444

 
266,221

Total liabilities
1,550,842

 
1,479,217

Shareholders' equity
2,163,053

 
1,994,640

Total liabilities and shareholders' equity
$
3,713,895

 
$
3,473,857







IDEX CORPORATION
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
 
Nine Months Ended September 30,
 
2019
 
2018
Cash flows from operating activities
 
 
 
Net income
$
328,671

 
$
312,436

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Asset impairments
9,680

 

Depreciation and amortization
29,599

 
29,725

Amortization of intangible assets
27,747

 
29,505

Amortization of debt issuance expenses
1,013

 
998

Share-based compensation expense
20,620

 
19,814

Deferred income taxes
11,528

 
(1,480
)
Non-cash interest expense associated with forward starting swaps
4,737

 
4,869

Changes in (net of the effect from acquisitions):
 
 
 
Receivables
(2,071
)
 
(34,057
)
Inventories
(16,987
)
 
(27,903
)
Other current assets
(19,186
)
 
7,635

Trade accounts payable
2,807

 
(4,420
)
Accrued expenses
(23,222
)
 
33

Other - net
1,966

 
(11,402
)
Net cash flows provided by operating activities
376,902

 
325,753

Cash flows from investing activities
 
 
 
Purchases of property, plant and equipment
(36,773
)
 
(39,856
)
Purchase of intellectual property

 
(4,000
)
Acquisition of businesses, net of cash acquired
(87,180
)
 
(20,205
)
Proceeds from disposal of fixed assets
957

 
211

Other - net
407

 
(1,180
)
Net cash flows used in investing activities
(122,589
)
 
(65,030
)
Cash flows from financing activities
 
 
 
Payments under revolving credit facilities

 
(11,128
)
Payments under other long-term borrowings
(49,923
)
 

Dividends paid
(109,227
)
 
(94,913
)
Proceeds from stock option exercises
35,595

 
26,793

Repurchases of common stock
(54,668
)
 
(50,654
)
Shares surrendered for tax withholding
(12,583
)
 
(11,260
)
Settlement of foreign exchange contracts

 
6,593

Other - net
(1,865
)
 

Net cash flows used in financing activities
(192,671
)
 
(134,569
)
Effect of exchange rate changes on cash and cash equivalents
(12,064
)
 
(10,337
)
Net increase in cash
49,578

 
115,817

Cash and cash equivalents at beginning of year
466,407

 
375,950

Cash and cash equivalents at end of period
$
515,985

 
$
491,767







IDEX CORPORATION
Company and Segment Financial Information - Reported
(dollars in thousands)
(unaudited)
 
 
 Three Months Ended
September 30,
(a)
 
Nine Months Ended
September 30,
(a)
 
 
2019
 
2018
 
2019
 
2018
 
Fluid & Metering Technologies
 
 
 
 
 
 
 
 
Net sales
$
240,861

 
$
239,213

 
$
729,572

 
$
714,346

 
Operating income (b)
77,481

 
69,755

 
223,493

 
207,149

 
Operating margin
32.2
%
 
29.2
%
 
30.6
%
 
29.0
%
 
EBITDA
$
82,693

 
$
74,844

 
$
239,534

 
$
222,994

 
EBITDA margin
34.3
%
 
31.3
%
 
32.8
%
 
31.2
%
 
Depreciation and amortization
$
5,507

 
$
5,500

 
$
16,653

 
$
16,901

 
Capital expenditures
3,627

 
6,487

 
10,207

 
15,142

 
 
 
 
 
 
 
 
 
 
Health & Science Technologies
 
 
 
 
 
 
 
 
Net sales
$
229,610

 
$
222,426

 
$
687,153

 
$
670,904

 
Operating income (b)
40,170

 
49,144

 
151,087

 
153,519

 
Operating margin
17.5
%
 
22.1
%
 
22.0
%
 
22.9
%
 
EBITDA
$
49,194

 
$
57,745

 
$
178,889

 
$
184,659

 
EBITDA margin
21.4
%
 
26.0
%
 
26.0
%
 
27.5
%
 
Depreciation and amortization
$
10,296

 
$
9,381

 
$
29,438

 
$
30,860

 
Capital expenditures
4,984

 
8,614

 
16,201

 
17,296

 
 
 
 
 
 
 
 
 
 
Fire & Safety/Diversified Products
 
 
 
 
 
 
 
 
Net sales
$
154,543

 
$
161,832

 
$
474,745

 
$
485,305

 
Operating income (b)
41,967

 
44,726

 
125,909

 
130,162

 
Operating margin
27.2
%
 
27.6
%
 
26.5
%
 
26.8
%
 
EBITDA
$
45,625

 
$
47,925

 
$
136,381

 
$
144,398

 
EBITDA margin
29.5
%
 
29.6
%
 
28.7
%
 
29.8
%
 
Depreciation and amortization
$
3,566

 
$
3,541

 
$
10,745

 
$
10,912

 
Capital expenditures
2,257

 
3,787

 
8,744

 
7,232

 
 
 
 
 
 
 
 
 
 
Corporate Office and Eliminations
 
 
 
 
 
 
 
 
Intersegment sales eliminations
$
(768
)
 
$
(583
)
 
$
(2,894
)
 
$
(983
)
 
Operating income (b)
(17,853
)
 
(18,492
)
 
(55,659
)
 
(61,183
)
 
EBITDA
(17,443
)
 
(17,709
)
 
(53,329
)
 
(59,609
)
 
Depreciation and amortization
154

 
184

 
510

 
557

 
Capital expenditures
163

 

 
1,621

 
186

 
 
 
 
 
 
 
 
 
 
Company
 
 
 
 
 
 
 
 
Net sales
$
624,246

 
$
622,888

 
$
1,888,576

 
$
1,869,572

 
Operating income
141,765

 
145,133

 
444,830

 
429,647

 
Operating margin
22.7
%
 
23.3
%
 
23.6
%
 
23.0
%
 
EBITDA
$
160,069

 
$
162,805

 
$
501,475

 
$
492,442

 
EBITDA margin
25.6
%
 
26.1
%
 
26.6
%
 
26.3
%
 
Depreciation and amortization (c)
$
19,523

 
$
18,606

 
$
57,346

 
$
59,230

 
Capital expenditures
11,031

 
18,888

 
36,773

 
39,856






IDEX CORPORATION
Company and Segment Financial Information - Adjusted
(dollars in thousands)
(unaudited)
 
 
 Three Months Ended
September 30,
(a)
 
Nine Months Ended
September 30,
(a)
 
 
2019
 
2018
 
2019
 
2018
 
Fluid & Metering Technologies
 
 
 
 
 
 
 
 
Net sales
$
240,861

 
$
239,213

 
$
729,572

 
$
714,346

 
Adjusted operating income (b)
77,481

 
70,582

 
224,423

 
208,462

 
Adjusted operating margin
32.2
%
 
29.5
%
 
30.8
%
 
29.2
%
 
Adjusted EBITDA
$
82,693

 
$
75,671

 
$
240,464

 
$
224,307

 
Adjusted EBITDA margin
34.3
%
 
31.6
%
 
33.0
%
 
31.4
%
 
Depreciation and amortization
$
5,507

 
$
5,500

 
$
16,653

 
$
16,901

 
Capital expenditures
3,627

 
6,487

 
10,207

 
15,142

 
 
 
 
 
 
 
 
 
 
Health & Science Technologies
 
 
 
 
 
 
 
 
Net sales
$
229,610

 
$
222,426

 
$
687,153

 
$
670,904

 
Adjusted operating income (b)
54,706

 
52,260

 
165,953

 
158,817

 
Adjusted operating margin
23.8
%
 
23.5
%
 
24.2
%
 
23.7
%
 
Adjusted EBITDA
$
63,730

 
$
60,861

 
$
193,755

 
$
189,957

 
Adjusted EBITDA margin
27.8
%
 
27.4
%
 
28.2
%
 
28.3
%
 
Depreciation and amortization
$
10,296

 
$
9,381

 
$
29,438

 
$
30,860

 
Capital expenditures
4,984

 
8,614

 
16,201

 
17,296

 
 
 
 
 
 
 
 
 
 
Fire & Safety/Diversified Products
 
 
 
 
 
 
 
 
Net sales
$
154,543

 
$
161,832

 
$
474,745

 
$
485,305

 
Adjusted operating income (b)
42,071

 
44,786

 
126,832

 
130,589

 
Adjusted operating margin
27.2
%
 
27.7
%
 
26.7
%
 
26.9
%
 
Adjusted EBITDA
$
45,729

 
$
47,985

 
$
137,304

 
$
144,825

 
Adjusted EBITDA margin
29.6
%
 
29.7
%
 
28.9
%
 
29.8
%
 
Depreciation and amortization
$
3,566

 
$
3,541

 
$
10,745

 
$
10,912

 
Capital expenditures
2,257

 
3,787

 
8,744

 
7,232

 
 
 
 
 
 
 
 
 
 
Corporate Office and Eliminations
 
 
 
 
 
 
 
 
Intersegment sales eliminations
$
(768
)
 
$
(583
)
 
$
(2,894
)
 
$
(983
)
 
Adjusted operating income (b)
(17,197
)
 
(17,874
)
 
(54,956
)
 
(59,970
)
 
Adjusted EBITDA
(16,787
)
 
(17,091
)
 
(52,626
)
 
(58,396
)
 
Depreciation and amortization
154

 
184

 
510

 
557

 
Capital expenditures
163

 

 
1,621

 
186

 
 
 
 
 
 
 
 
 
 
Company
 
 
 
 
 
 
 
 
Net sales
$
624,246

 
$
622,888

 
$
1,888,576

 
$
1,869,572

 
Adjusted operating income 
157,061

 
149,754

 
462,252

 
437,898

 
Adjusted operating margin
25.2
%
 
24.0
%
 
24.5
%
 
23.4
%
 
Adjusted EBITDA
$
175,365

 
$
167,426

 
$
518,897

 
$
500,693

 
Adjusted EBITDA margin
28.1
%
 
26.9
%
 
27.5
%
 
26.8
%
 
Depreciation and amortization (c)
$
19,523

 
$
18,606

 
$
57,346

 
$
59,230

 
Capital expenditures
11,031

 
18,888

 
36,773

 
39,856

 
 
 
 
 
 
 
 
 
(a)
Three and nine month data includes the results of Velcora (July 2019) and Finger Lakes Instrumentation (July 2018) in the Health & Science Technologies segment from the date of acquisition.
(b)
Segment operating income excludes unallocated corporate operating expenses which are included in Corporate Office and Eliminations.
(c)
Depreciation and amortization excludes amortization of debt issuance costs.



q319slidesfinal
Third Quarter 2019 Earnings October 30, 2019 IDEX Proprietary & Confidential


 
AGENDA • IDEX’s Overview and Outlook • Q3 Financial Performance • Segment Performance • Fluid & Metering Technologies • Health & Science Technologies • Fire & Safety / Diversified Products • 2019 Guidance Summary • Q&A Brand names shown in this presentation are registered trademarks of IDEX Corporation and/or its subsidiaries IDEX Proprietary & Confidential 1


 
Replay Information • Dial toll–free: 877.660.6853 • International: 201.612.7415 • Conference ID: #13684164 • Log on to: www.idexcorp.com Brand names shown in this presentation are registered trademarks of IDEX Corporation and/or its subsidiaries IDEX Proprietary & Confidential 2


 
Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures This presentation and discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the company believes,” “the company intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors, and levels of capital spending in certain industries – all of which could have a material impact on order rates and IDEX’s results, particularly in light of the low levels of order backlogs it typically maintains; its ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the company operates; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the company’s most recent annual report on Form 10-K filed with the SEC and the other risks discussed in the company’s filings with the SEC. The forward-looking statements included in this presentation and discussion are only made as of today’s date, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information in this presentation and discussion. This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or our earnings release for the three-month period ending September 30, 2019, which is available on our website. Brand names shown in this presentation are registered trademarks of IDEX Corporation and/or its subsidiaries IDEX Proprietary & Confidential 3


 
IDEX Q3 Financial Performance (Dollars in millions, excl. EPS) Sales Adjusted EPS* 8% increase Organic: Flat $623 $624 $1.41 $1.52 $2.00 $700 $1.50 $500 $1.00 $0.50 $300 $0.00 Q3 Q3 2018 2019 2018 2019 Adjusted Operating Margin* Free Cash Flow 120 bps increase 28% increase $146 25.2% 24.0% 26.0% $150 $114 24.0% 22.0% $100 20.0% 18.0% $50 Q3 Q3 2018 2019 2018 2019 * Operating margin and EPS data adjusted for a fair value inventory step-up charge ($3.3M in Q3 2019) and restructuring expenses ($12.0M in Q3 2019 and $4.6M in Q3 2018). Strong operating margin expansion of 120 bps helped drive an 8 percent EPS increase Brand names shown in this presentation are registered trademarks of IDEX Corporation and/or its subsidiaries IDEX Proprietary & Confidential 4


 
Fluid & Metering Technologies (Dollars in millions) Orders Sales Adjusted Operating Margin* Organic: Flat Organic: 2% increase 270 bps increase $239 $241 32.2% $236 $233 $300 $300 33.0% 29.5% $200 $200 29.0% $100 $100 $0 $0 25.0% Q3 Q3 Q3 2018 2019 2018 2019 2018 2019 Q3 Sales Mix: Organic 2% Q3 Highlights: ❑ Growth in Pumps, Valves and Energy due to strong execution on targeted growth initiatives FX -1% ❑ North American Industrial short cycle book and turn activity experienced slowdown Reported Sales 1% ❑ Municipal water remained solid ❑ Market dynamics within the agriculture market continues to put pressure on our Banjo business * Operating margin data adjusted for restructuring expenses ($0.8M in Q3 2018). Strong price capture and operational efficiencies drove a 270 bps increase in operating margin Brand names shown in this presentation are registered trademarks of IDEX Corporation and/or its subsidiaries IDEX Proprietary & Confidential 5


 
Health & Science Technologies (Dollars in millions) Orders Sales Adjusted Operating Margin* Organic: 6% decrease Organic: 1% increase 30 bps increase 23.8% $230 23.5% $219 $211 $222 $250 $250 24.0% $200 $200 22.0% $150 $150 $100 $100 20.0% Q3 Q3 Q3 2018 2019 2018 2019 2018 2019 Q3 Sales Mix: Organic 1% Q3 Highlights: ❑ Seals experienced continued market pressure in Semicon and Auto along Acquisitions 3% with weakened industrial activity ❑ NPD efforts and collaboration with key customers drove strong sales FX -1% performance in Life Sciences, OEM blanket timing impacted orders ❑ Gast wins with NPD offset by a slow down in industrial distribution Reported Sales 3% ❑ MPT shipped long lead time projects, reversing the negative trend experienced in first half of year * Operating margin data adjusted for a fair value inventory step-up charge ($3.3M in Q3 2019) and restructuring expenses ($11.2M in Q3 2019 and $3.1M in Q3 2018). Life Sciences and Pharma operations continue to outperform Brand names shown in this presentation are registered trademarks of IDEX Corporation and/or its subsidiaries IDEX Proprietary & Confidential 6


 
Fire & Safety / Diversified Products (Dollars in millions) Orders Sales Adjusted Operating Margin* Organic: 9% decrease Organic: 3% decrease 50 bps decrease 27.7% $160 $162 $154 27.2% $200 30.0% $200 $143 $150 $150 25.0% $100 $100 20.0% $50 $50 Q3 Q3 Q3 2018 2019 2018 2019 2018 2019 Q3 Sales Mix: Organic -3% Q3 Highlights: ❑ Core OEM and Municipal markets continue to outperform in Fire business FX -2% ❑ Challenges within Rescue due to funding delays, and lower large project tenders Reported Sales -5% ❑ Targeted growth initiatives continued to drive Band-IT performance ❑ Tough comps against prior year large project wins at Dispensing * Operating margin data adjusted for restructuring expenses ($0.1M in Q3 2019 and 2018). Tough comparable due to large project orders in prior year Brand names shown in this presentation are registered trademarks of IDEX Corporation and/or its subsidiaries IDEX Proprietary & Confidential 7


 
2019 Guidance Summary Q4 2019 – EPS estimate range: $1.33 – $1.35 – Organic revenue growth: Flat – Operating margin: ~23.5% – Tax rate: ~22.0% – FX impact: ~1.0% topline headwind based on September 30, 2019 FX rates – Corporate costs: ~$18 million FY 2019 – EPS estimate range: $5.80 – $5.82 – Organic revenue growth: ~2% – Operating margin: ~24.0% – FX impact: ~2.0% topline headwind based on September 30, 2019 FX rates – Other modeling items: • Tax rate: ~20.5% • Cap Ex: ~ $55M • Free cash flow will be approximately 105% of net income • Corporate costs: ~$73 million • EPS estimate excludes all future acquisitions and associated costs and any future restructuring expenses Brand names shown in this presentation are registered trademarks of IDEX Corporation and/or its subsidiaries IDEX Proprietary & Confidential 8